Literature DB >> 12755239

Pneumocystis carinii pneumonia in HIV/AIDS patients at an urban district hospital in Kenya.

J M Chakaya1, C Bii, L Ng'ang'a, E Amukoye, T Ouko, L Muita, S Gathua, J Gitau, I Odongo, J M Kabanga, K Nagai, S Suzumura, Y Sugiura.   

Abstract

BACKGROUND: Pneumocystis carinii pneumonia has generally been regarded to be an uncommon opportunistic infection in HIV infected individuals in sub-Saharan Africa. The reason for this has not been clear but postulates included a lack of suitable pathogenic types in the African environment, diagnostic difficulties and the more commonly held belief that African HIV infected individuals were dying early from common non-opportunistic pathogens before severe degrees of immunosuppression occured. Recently a trend has emerged at the Mbagathi district hospital whereby an increasing number of HIV infected patients are empirically treated for Pneumocystis carinii pneumonia (PCP) based on clinical and radiological features.
OBJECTIVE: To determine the prevalence of PCP and clinical outcomes of HIV infected patients presenting at the Mbagathi District Hospital, Nairobi with the presumptive diagnosis of PCP.
SETTING: Mbagathi District Hospital, a 169-bed public hospital in Nairobi, Kenya.
METHODS: Patients presenting with a sub-acute onset of cough and dyspnoea were eligible for the study if they were found to have bilateral pulmonary shadows and had negative sputum smears for AFBS. Consenting patients who had no contraindication to fiberoptic bronchoscopy had a clinical evaluation which was followed with a fiberoptic bronchoscopy procedure where bronchoalveolar lavage fluid (BALF) was obtained. BALF was examined for cysts of P. carinii using toluidine blue stain and immunofluorescent antibody test (IFAT). BALF was also processed for fungi, bacteria and mycobacteria using routine procedures. Standard treatment with high dose cotrimoxazole was offered to all patients who were then followed up until discharge from hospital or death whichever came first.
RESULTS: Between June 1999 and August 2000 a total of 63 patients were referred for bronchoscopy. Of these four declined to undergo the fiberoptic bronchoscopy procedure, four died before the procedure could be done, one was judged too sick to undergo the procedure and three had been on cotrimoxazole for longer than five days. Thus 51 patients underwent bronchoscopy. Pneumocystis carinii stain was positive in 19 (37.2%) while death occured in 16 (31.4%) of the 51 patients. There were more deaths in those without PCP but this difference was not statistically significant (odds ratio 0.68 (95% CI 0.35-1.32; P=0.2).
CONCLUSION: PCP was found to be common in HIV infected patients presenting with clinical and radiological features of the disease. The mortality rate for patients with a presumptive diagnosis of PCP is high. This study suggests that cotrimoxazole preventive therapy may be a useful intervention in symptomatic HIV infected patients in Kenya for the prevention of PCP and may avert deaths from this disease.

Entities:  

Mesh:

Year:  2003        PMID: 12755239     DOI: 10.4314/eamj.v80i1.8663

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  13 in total

1.  High prevalence of dihydropteroate synthase mutations in Pneumocystis jirovecii isolated from patients with Pneumocystis pneumonia in South Africa.

Authors:  Leigh Dini; Mignon du Plessis; John Frean; Victor Fernandez
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

2.  Etiology of suspected pneumonia in adults admitted to a high-dependency unit in Blantyre, Malawi.

Authors:  Thomas K Hartung; Daniel Chimbayo; Joep J G van Oosterhout; Tarsizio Chikaonda; Gerard J J van Doornum; Eric C J Claas; Willem J G Melchers; Malcolm E Molyneux; Ed E Zijlstra
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

Review 3.  Pathological and protective immunity to Pneumocystis infection.

Authors:  Taylor Eddens; Jay K Kolls
Journal:  Semin Immunopathol       Date:  2014-11-25       Impact factor: 9.623

4.  Aetiology and prognosis of community-acquired pneumonia at the Adult University Teaching Hospital in Zambia.

Authors:  L M Ziko; T W Hoffman; S Fwoloshi; D Chanda; Y M Nampungwe; D Patel; H Bobat; A Moonga; L Chirwa; L Hachaambwa; K J Mateyo
Journal:  PLoS One       Date:  2022-07-15       Impact factor: 3.752

Review 5.  Pneumocystis jirovecii pneumonia in developing countries.

Authors:  Y de Armas Rodríguez; G Wissmann; A L Müller; M A Pederiva; M C Brum; R L Brackmann; V Capó de Paz; E J Calderón
Journal:  Parasite       Date:  2011-08       Impact factor: 3.000

6.  Cost-effectiveness analysis of diagnostic options for pneumocystis pneumonia (PCP).

Authors:  Julie R Harris; Barbara J Marston; Nalinee Sangrujee; Desiree DuPlessis; Benjamin Park
Journal:  PLoS One       Date:  2011-08-15       Impact factor: 3.240

7.  Pneumocystis pneumonia in HIV-positive adults, Malawi.

Authors:  Joep J G van Oosterhout; Miriam K Laufer; M Arantza Perez; Stephen M Graham; Nelson Chimbiya; Phillip C Thesing; Miriam J Alvarez-Martinez; Paul E Wilson; Maganizo Chagomerana; Eduard E Zijlstra; Terrie E Taylor; Christopher V Plowe; Steven R Meshnick
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883

8.  Pneumocystis jirovecii Pneumonia in Africa: Impact and Implications of Highly Sensitive Diagnostic Technologies.

Authors:  Olga Matos
Journal:  N Am J Med Sci       Date:  2012-10

9.  Case Report: Pulmonary Kaposi Sarcoma in a non-HIV patient.

Authors:  Arber Kodra; Maciej Walczyszyn; Craig Grossman; Daniel Zapata; Tarak Rambhatla; Bushra Mina
Journal:  F1000Res       Date:  2015-10-07

Review 10.  Pneumocystis jirovecii pneumonia in tropical and low and middle income countries: a systematic review and meta-regression.

Authors:  David M Lowe; Molebogeng X Rangaka; Fabiana Gordon; Chris D James; Robert F Miller
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.